Table 2 Multivariate analysis of factors potentially predictive of survival in patients with endometrial cancer (N = 477).

From: Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer

Parameters

Relapse-free survival

Disease-specific survival

HR (95% CI)

P-value

HR (95% CI)

P-value

FIGO stage

 II–IV vs. I

3.38 (1.82–6.27)

<0.001

2.32 (1.06–5.08)

0.036

LVSI

 Present vs. absent

1.74 (1.00–2.99)

0.048

2.55 (1.32–4.89)

0.005

VISTA in ICs

 Positive vs. negative

0.55 (0.33–0.91)

0.021

0.52 (0.29–0.93)

0.029

Molecular subtype

 

<0.001

 

<0.001

 POLEmut vs. NSMP

0.0 (0.0–7.5E227)

0.964

0.0 (0.0–4.5E290)

0.969

 MMRd vs. NSMP

0.92 (0.43–1.97)

0.827

0.43 (0.16–1.15)

0.091

 p53mut vs. NSMP

2.81 (1.46–5.39)

0.002

1.59 (0.73–3.45)

0.24

Tumor grade

 High vs. low

–

–

2.55 (1.06–6.10)

0.036

  1. CI confidence interval, FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio, ICs immune cells, LVSI lymphovascular space invasion, MMRd mismatch repair-deficient, NSMP nonspecific molecular profile, p53mut P53 mutation, POLEmut polymerase epsilon mutation, VISTA V-domain Ig suppressor of T-cell activation.
Back to article page